Bioline Rx Ltd ADR (BLRX) concluded trading on Thursday at a closing price of $0.26, with 30.03 million shares of worth about $7.81 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -51.76% during that period and on Thursday the price saw a gain of about 19.44%. Currently the company’s common shares owned by public are about 89.11M shares, out of which, 88.62M shares are available for trading.
Stock saw a price change of 9.51% in past 5 days and over the past one month there was a price change of -12.29%. Year-to-date (YTD), BLRX shares are showing a performance of 19.44% which decreased to -83.29% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.19 but also hit the highest price of $1.59 during that period. The average intraday trading volume for Bioline Rx Ltd ADR shares is 1.10 million. The stock is currently trading 12.23% above its 20-day simple moving average (SMA20), while that difference is down -23.46% for SMA50 and it goes to -57.26% lower than SMA200.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Bioline Rx Ltd ADR (NASDAQ: BLRX) currently have 89.11M outstanding shares and institutions hold larger chunk of about 3.72% of that.
The stock has a current market capitalization of $22.78M and its 3Y-monthly beta is at 1.46. It has posted earnings per share of -$0.27 in the same period. It has Quick Ratio of 1.37 while making debt-to-equity ratio of 3.48. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for BLRX, volatility over the week remained 23.72% while standing at 13.37% over the month.
Stock’s fiscal year EPS is expected to rise by 91.44% while it is estimated to decrease by -8.69% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Maxim Group on May 18, 2017 offering a Buy rating for the stock and assigned a target price range of between $1 and $3 to it. Coverage by Rodman & Renshaw stated Bioline Rx Ltd ADR (BLRX) stock as a Buy in their note to investors on February 13, 2017, suggesting a price target of $3 for the stock. On August 12, 2016, Maxim Group Downgrade their recommendations, while on August 17, 2015, Maxim Group Reiterated their ratings for the stock with a price target of $4. Stock get a Buy rating from ROTH Capital on July 27, 2015.
